FDA Vouchers and Obesity Drug Benefits: What You Need to Know
- so far, we plan to catch up on our reading and promenade with the official mascots.
- More than half a dozen major drugmakers are participating in the Trump governance's speedier review program for new medicines, but others are hesitant due to potential legal risks,...
And so, another working week will soon draw to a close. Not a moment too soon, yes? We’re still shaping up our weekend plans. so far, we plan to catch up on our reading and promenade with the official mascots. We’re also holding another listening party – it’s a weekly event – where the rotation will likely include this, this, this, this and this. What about you? Depending on where you live, you might enjoy the outdoors with a walk or a drive. If it’s cold, a good book or a show sounds nice. Or maybe cook a nice meal. Whatever you do, have a grand time, but be safe. Just a reminder – we’ll see you on Tuesday, as there’s a long weekend due to a holiday commemorating civil rights. Enjoy, and see you soon…
More than half a dozen major drugmakers are participating in the Trump governance’s speedier review program for new medicines, but others are hesitant due to potential legal risks, Reuters reports. Under the FDA commissioner’s National Priority Voucher Program, unveiled in June, FDA chief Marty Makary can issue approval decisions in one to two months on drugs deemed critical to public health or national security, or those manufactured in the U.S. or offered at low prices. However, pharma executives and advisers worry a two-month review might not provide enough scientific rigor to evaluate a medicine’s safety and efficacy. That could undermine the FDA’s credibility and increase legal risk for drugmakers.